Ọgọst21,E nyela nyocha mbụ site n'aka Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA). A na-akwado nkwenye a maka ndị ọrịa toro eto nwere ọrịa lymphoma follicular relapsed ma ọ bụ refractory (FL), nke bụ nnukwu ihe ize ndụ nke ọrịa kansa mkpụrụ ndụ B.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Banyere Epcoritamab
Epcoritamab bụ ọgwụ mgbochi IgG1 nke e ji teknụzụ DuoBody nke Genmab mepụtara ma na-enye ya n'okpuru akpụkpọ ahụ. Emebere teknụzụ DuoBody-CD3 nke Genmab iji duzie mkpụrụ ndụ T cytotoxic n'ụzọ nhọrọ iji kpalite nzaghachi mgbochi ọrịa megide ụdị mkpụrụ ndụ ndị a na-achọ. Emebere Epcoritamab ka ọ jikọọ na CD3 na mkpụrụ ndụ T na CD20 na mkpụrụ ndụ B n'otu oge ma na-akpali ogbugbu mkpụrụ ndụ CD20+ nke T-cell na-akpata.
Banyere Follicular Lymphoma (FL)
FL na-abụkarị ụdị lymphoma na-abụghị Hodgkin (NHL) nke na-adịghị arụ ọrụ nke ọma (ma ọ bụ nke na-eto nwayọ nwayọ) nke sitere na B-lymphocytes ma bụrụ ụdị nke abụọ kachasị na NHL na-aza maka pasent 20-30 nke ikpe niile. Ihe dị ka mmadụ 15,000 na-etolite FL kwa afọ na USii ma a na-ewere ya dị ka ihe a na-apụghị ịgwọta site na usoro ọgwụgwọ ugbu a. iii Ndị ọrịa na-alaghachi azụ, na nlọghachi ọ bụla, mgbaghara na oge iji gaa ọgwụgwọ ọzọ na-adị mkpụmkpụ.iv Ka oge na-aga, mgbanwe gaa na nnukwu lymphoma B-cell diffuse (DLBCL), ụdị ike siri ike nke NHL jikọtara ya na nsonaazụ ndụ adịghị mma, nwere ike ime na ihe karịrị pasent 25 nke ndị ọrịa FL.
EPCORE FL-1 (NCT05409066) bụ nnwale nyocha nke Phase 3 nke mepere emepe iji nyochaa nchekwa na irè nke epcoritamab gbakwunyere rituximab na lenalidomide (R2) megide R2 naanị na ndị ọrịa nwere ọrịa lymphoma follicular relapsed/refractory (R/R) (FL).
Ọgọst 7,Genmab A/Sekwuputala nsonaazụ dị mma nke nnwale EPCORE FL-1 nke Phase 3 nke na-enyocha epcoritamab subcutaneous, ọgwụ mgbochi bispecific, yana rituximab na lenalidomide (R®2) megide R2 naanị maka ọgwụgwọ nke ndị okenye nwere ọrịa lymphoma follicular relapse ma ọ bụ refractory (R/R) (FL). Ọmụmụ ihe ahụ zutere isi ihe abụọ dị mkpa nke ọnụego nzaghachi zuru oke (ORR, p-value < 0.0001) na ndụ na-enweghị ọganihu (PFS, HR 0.21, p-value < 0.0001), na-egosi ọdịiche dị mkpa na nke bara uru na ọgwụgwọ na njedebe abụọ ahụ, na-ebelata ihe egwu nke ọganihu ọrịa ma ọ bụ ọnwụ site na 79%.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Oge ozi: Sep-05-2025